The association of PTEN loss with resistance to immunotherapy was generally confirmed in various recent studies using short-term tumor cell lines and matched tumor samples from melanoma patients progressing on immune checkpoint inhibitors (Lim et al. 2023), melanoma patients’ material (Cabrita et al. 2020) and also preclinical models of prostate cancer (Lin et al. 2021). The gene discussed is PTEN; the disease is neoplasm.